在帕金森病模型中,GSK-3β抑制剂通过调节TFEB来放大自-溶酶途径
Jiahong Zhong1, Xihui Yu2, Yunming Zhong1
1Department of Clinical Pharmacy, Meizhou People's Hospital (Huangtang Hospital), Meizhou 514031, China.
Experimental neurology
|November 3, 2024
概括
抑制糖原合成酶激酶-3β (GSK-3β) 通过增强TFEB-自-溶解体通路,改善神经元功能和运动缺陷,延缓帕金森病的进展. 这为帕金森病提供了潜在的新疗法策略.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,主要导致运动功能障碍.
- 糖原合成酶激酶-3β (GSK-3β) 与神经退行性疾病病理学有关.
- 在PD中GSK-3β抑制剂的确切作用及其机制仍然不清楚.
研究的目的:
- 研究GSK-3β抑制对帕金森病进展的影响.
- 在PD模型中阐明基底的GSK-3β抑制的分子机制.
- 评估GSK-3β抑制剂作为PD的潜在治疗标.
主要方法:
- 使用MPP+或MPTP诱导的帕金森病的体外和小鼠模型.
- 服用GSK-3β抑制剂和对线粒体损伤,亡和神经元损失的评估影响.
- 通过使用siRNA沉默,研究了转录因子EB (TFEB) 和自-溶酶体通路 (ALP) 的作用.
- 在MPTP诱导的PD小鼠模型中评估运动功能和协调.
主要成果:
- 在PD模型中,GSK-3β抑制缓解了线粒体损伤,亡和神经元损失.
- 抑制GSK-3β促进了TFEB的核转位,增强了自-溶解体通路 (ALP).
- TFEB基因沉默否定了GSK-3β抑制剂对ALP激活的有益作用.
- 在PD小鼠中,GSK-3β抑制改善了运动功能,减少了α-synuclein聚合,并减少了神经元损伤.
结论:
- 抑制GSK-3β活动会延迟帕金森病的病理过程.
- TFEB-自-溶解体通路是GSK-3β抑制剂在PD中的有效性的关键调解者.
- 抑制GSK-3β代表了对帕金森病的有前途的治疗策略.
相关概念视频
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K


